Addex Therapeutics (ADXN) Upgraded by Zacks Investment Research to Hold

Addex Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Addex Therapeutics Upgraded by Zacks Investment Research on 10-11-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of Addex Therapeutics traded down -$0.18 on Monday, reaching $8.77. 4540 shares of the stock traded hands, compared to its average volume of 1852. Shares of Addex Therapeutics were trading at $8.77 on Monday. The firm’s 50 day moving average is $9.56 and its 200 day moving average is $10.47.Addex Therapeutics has a 12 month low of $8.68 and a 12 month high of $35.00. While on yearly highs and lows, Addex Therapeutics’s today has traded high as $8.91 and has touched $8.68 on the downward trend. See More Analyst Rating at: RATING

Addex Therapeutics Earnings and What to expect: 

Addex Therapeutics last issued its earnings data on August 5th, 2021. The reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by $0.12. The business earned $1.18 million during the quarter, compared to analyst estimates of $0.26 million. Addex Therapeutics has generated ($3.07) earnings per share over the last year (($2.61) diluted earnings per share). Earnings for Addex Therapeutics are expected to grow in the coming year, from ($2.64) to ($2.59) per share. Addex Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 2nd, 2021 based off prior year’s report dates.

Earnings for Addex Therapeutics are expected to grow in the coming year, from ($2.64) to ($2.59) per share. The P/E ratio of Addex Therapeutics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Addex Therapeutics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Addex Therapeutics has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Addex Therapeutics (ADXN) Moving Average Technical Analysis

5 day Moving Average is $8.94 And 5 day price change is -$0.72 (-7.63%)  with average volume for 5 day average is 2,100. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $9.34 and 20 day price change is -$1.13 (-11.56%) and average 20 day moving volume is 1,845. 50 day moving average is $9.56  and 50 day price change is -$0.87 ( -9.11%)  and with average volume for 50 days is : 2,726. 200 day moving average is $10.47  and 200 day price change is -$3.32 (-27.67%)  and with average volume for 200 days is : 40,799.

Other owners latest trading in Addex Therapeutics :

  • On 8/12/2021 shares held by New Leaf Venture Partners L.L.C. were 50,000 which equates to market value of $0.48M and appx 0.10% owners of Addex Therapeutics
  • On 8/2/2021 shares held by NEA Management Company LLC were 180,000 which equates to market value of $17.21M and appx 0.20% owners of Addex Therapeutics
  • On 5/21/2021 shares held by Citadel Advisors LLC were 11,604 which equates to market value of $0.12M and appx 0.00% owners of Addex Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 6.20% for Addex Therapeutics

See More Analyst Rating at: RATING